Aleor Dermaceuticals

Aleor Dermaceuticals has received approval from the U.S. Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for 0.05% Desonide Ointment. Desonide Ointment is a low-potency corticosteroid that alleviates inflammatory and pruritic symptoms of corticosteroid-responsive dermatoses. Aleor’s product portfolio includes creams, gels, ointments, shampoos, lotions, solutions, sprays, foams, microsponge, and nanoparticle platform products.